xpertsystems/hconc009-sample

HC-ONC-009 — 黑色素瘤合成队列（样本）是一个完全合成的黑色素瘤患者队列数据集，涵盖世界卫生组织（WHO）的六种亚型（包括浅表扩散型、结节型、恶性雀斑样痣型、肢端雀斑样黑色素瘤、葡萄膜黑色素瘤和促结缔组织增生性黑色素瘤），并基于AJCC第8版TNM分期系统（通过Breslow厚度、溃疡状态和有丝分裂率计算）。数据集包含500名患者的105个特征列，涉及人口统计学、分期、基因组学（如BRAF、NRAS、KIT等突变）、手术（符合NCCN指南）、现代免疫治疗（如Pembrolizumab、Nivolumab等方案）、靶向治疗（如BRAF/MEK抑制剂）、转移器官倾向、辅助放疗和免疫治疗，以及校准的生存终点（如总生存期、无复发生存期）。数据集根据SEER注册表、NCCN指南和多项临床试验（如KEYNOTE-006、CheckMate-067）进行校准，确保生物学和临床合理性，适用于黑色素瘤分析、建模、演示和教育，同时100%合成，无真实患者数据或隐私风险。文件格式为CSV单表，并包含验证报告和模式详细信息。HC-ONC-009 — Melanoma Synthetic Cohort (Sample) is a fully synthetic cohort dataset of melanoma patients, covering six WHO-defined subtypes including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, uveal melanoma, and desmoplastic melanoma. It is constructed based on the 8th edition of the AJCC TNM staging system, which is calculated using Breslow thickness, ulceration status, and mitotic rate. The dataset includes 105 feature columns for 500 patients, covering demographics, staging, genomics (e.g., mutations in BRAF, NRAS, KIT and other relevant genes), surgery compliant with NCCN guidelines, modern immunotherapeutic regimens (e.g., Pembrolizumab, Nivolumab and other approved protocols), targeted therapies (e.g., BRAF/MEK inhibitors), metastatic organ tropism, adjuvant radiotherapy and immunotherapy, as well as calibrated survival endpoints such as overall survival and recurrence-free survival. The dataset is calibrated against the SEER registry, NCCN guidelines, and multiple clinical trials including KEYNOTE-006 and CheckMate-067 to ensure biological and clinical plausibility. It is suitable for melanoma analysis, modeling, demonstration and education, and is 100% synthetic with no real patient data or associated privacy risks. The dataset is provided as a single CSV table, accompanied by validation reports and detailed schema information.